Product Overview Data Sheet Protocol
This vector is a constitutive mammalian expression vector designed to deliver exceptionally high levels of antibody expression. This circular vector features an enhanced, full-length CMV promoter and other expression elements that typically enable higher expression levels. It can be used in suspension-adapted cells, such as Expi293F™ and ExpiCHO™, for transient protein expression. Additionally, it can serve as a Geneticin®-selectable expression plasmid for engineering stable cell lines. The vector carries an ampicillin resistance gene.
Mouse IgM is the first antibody secreted by the adaptive immune system in response to a foreign antigen. Monomeric IgM is a heterotetramer of approximately 180 kDa. However, the secreted form of IgM exists predominantly in a pentameric configuration with a molecular weight greater than 900 kDa. The pentamer is connected at their Fc portions by a J, or joining chain (pFB-mIgJ).
Specifications of Antibody Expression Vector| Antibiotic Resistance | Ampicillin (AmpR) |
| Constitutive or Inducible System | Constitutive |
| Delivery Type | Transfection |
| Promoter | CMV |
| Product Type | Mammalian Expression Vector |
| Cloning Method | Restriction Enzyme (5’-AgeI; 3’-XhoI) or Homologous Assembly |
Contents & Storage
- 20 µg of pFB-CHIg-mM (pentamer) in Tris-EDTA buffer
- Store at -20°. Vectors are guaranteed stable for 6 months when properly stored.
Materials required for antibody generation and isotype switching
pFB-mIgJ with pFB-CLIg-mk or pFB-CLIg-ml1, pFB-CLIg-ml2 plasmid expressing the mouse kappa light chain or mouse lambda chain.
Vector usage
- Entire monoclonal mouse IgM antibodies production: cloning your heavy/light chain variable regions in the cloning sites to preserve the integrity of the heavy/light chain constant region.
- Isotype switching: pFB-CHIg-mM (pentamer) with pFB-mIgJ and pFB-CLIg-mk or pFB-CLIg-ml1, pFB-CLIg-ml2 plasmids are designed to switch a monoclonal antibody from one isotype to another, therefore, maintaining the generated new antibodies with the same antigen affinity (epitopes) but with different effector functions (enhanced or reduced or even disabled ADCC and CDC).
